Lundbeck
FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti
Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback
Lundbeck Strengthens Neuro-Rare Disease Portfolio with $2.6 Billion Acquisition of Longboard Pharmaceuticals
Lundbeck, Longboard Pharmaceuticals, Neuro-Rare Diseases, Acquisition, Biotech, Pharmaceutical Industry